Neisseria (e.g., Neisseria Gonorrhoeae, Etc.) Patents (Class 424/249.1)
-
Patent number: 7524509Abstract: An adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide is prepared to contain the component parts under a variety of conditions. The complex can be formulated with antigenic material to form immunogenic compositions, vaccines and immunotherapeutics. An induced immune response includes protective antibodies and/or type 1 cytokines is shown for a variety of protocols.Type: GrantFiled: March 11, 2002Date of Patent: April 28, 2009Assignee: ID Biomedical Corporation of QuebecInventors: David S. Burt, George H. Lowell, Gregory L. White, David Jones, Clement Rioux
-
Patent number: 7521549Abstract: The invention provides BASB041, 43, 44 and 48 polypeptides and polynucleotides encoding BASB041, 43, 44 and 48 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: January 9, 2004Date of Patent: April 21, 2009Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Jean-Louis Ruelle, Vincent George Christian Louis Verlant
-
Patent number: 7504111Abstract: The invention provides proteins from gonococcus (Neisseria gonorrhoeae), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. They are also useful for distinguishing between gonococcus and meningococcus and, in particular, between gonococcus and serogroup B meningococcus.Type: GrantFiled: February 12, 2002Date of Patent: March 17, 2009Assignee: Novartis Vaccines and Diagnostics S.R.L.Inventors: Maria Rita Fontana, Mariagrazia Pizza, Vega Masiganani, Elisabetta Monaci
-
Patent number: 7485304Abstract: A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating toxin, optionally comprising one or more amino acid additions, deletions or substitutions.Type: GrantFiled: April 6, 2006Date of Patent: February 3, 2009Assignee: Novartis Vaccines and Diagnostics SRLInventor: Rino Rappuoli
-
Publication number: 20080248065Abstract: The present invention generally provides methods and compositions for eliciting an immune response against Neisseria spp. bacteria in a subject, particularly against a Neisseria meningitidis serogroup B strain.Type: ApplicationFiled: January 23, 2006Publication date: October 9, 2008Inventors: Dan M. Granoff, Victor Chen-Hsi
-
Patent number: 7422754Abstract: The invention provides novel Neisseria meningitides (Nm) polypeptides and polynucleotides which cover the Nm genetic diversity, and which correspond to polypeptide of Nm outer membrane and/or periplasma, and to methods for producing such Nm compounds. Also provided are anti-Nm infection, and particularly diagnostic. prophylactic and therapeutic uses thereof.Type: GrantFiled: May 14, 2004Date of Patent: September 9, 2008Assignees: Institut National de la Sante et de la Recherche Medicale (Inserm), Max-Planck Gesellschaft zur Forderung des Wissenschaften E.V.Inventors: Xavier Nassif, Colin Tinsley, Silke Klee, Mark Achtman, Petra Merker
-
Patent number: 7399840Abstract: Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.Type: GrantFiled: February 3, 2004Date of Patent: July 15, 2008Assignee: ID Biomedical Corporation of QuebecInventors: David S. Burt, David H. Jones, George H. Lowell, Gregory L. White, Kirkor Torossian, Louis F. Fries, III, Martin Plante
-
Patent number: 7384645Abstract: A composition is prepared from a mixture of different vesicles, such as outer membrane vesicles (OMVs) and vaccines are based thereon. Another composition comprises in a single vesicle a combination of antigens and/or other vesicle components deriving from separate vesicles; again vaccines are prepared therefrom.Type: GrantFiled: December 17, 2002Date of Patent: June 10, 2008Assignee: Health Protection AgencyInventors: Keith Alan Foster, Andrew Richard Gorringe, Michael John Hudson, Karen Margaret Reddin, Andrew Robinson
-
Patent number: 7357932Abstract: Present invention provides a monoclonal antibody binding to Neisseria bacteria and its target antigen Ag473, which include the sequences of its polynucleotide and its amino acid, wherein the Neisseria bacteria can be Neisseria meningitidis or Neisseria gonorrhoeae; and wherein Ag473 can be made into a vaccine or a diagnostic or therapeutic reagent.Type: GrantFiled: June 16, 2004Date of Patent: April 15, 2008Assignee: Center of Disease Control Department of HealthInventor: Chiou-Ying Yang
-
Publication number: 20080025993Abstract: The present invention provides an isolated refolded NspA protein, and a method of preparing it.Type: ApplicationFiled: August 28, 2003Publication date: January 31, 2008Inventors: Ralph Biemans, Philippe Denoel, Christiane Feron, Carine Goraj, Jan Poolman, Vincent Weynants
-
Patent number: 7273611Abstract: The identification of a highly conserved, immunologically accessible antigen on the surface of Neisseria facilitates treatment, prophylaxis, and diagnosis of Neisseria diseases. This antigen is highly resistant to proteinase K and has an apparent molecular weight of 22 kDa on SDS-PAGE. Specific polynucleotides encoding proteins of this class have been isolated from three Neisseria meningitidis strains and from one Neisseria gonorrhoaea strain. These polynucleotides have been sequenced, and the corresponding full-length amino acid sequences of the encoded polypeptides have been deduced. Recombinant DNA methods for the production of the Neisseria surface protein, and antibodies that bind to this protein are also disclosed.Type: GrantFiled: October 6, 2000Date of Patent: September 25, 2007Assignee: ID Biomedical CorporationInventors: Bernard R. Brodeur, Denis Martin, Josee Hamel, Clement Rioux
-
Patent number: 7261901Abstract: The present invention is directed to novel polypeptides, polynucleotides and vaccines for use against Neisseria gonorrhoeae colonization or infection and/or Neisseria meningitidis colonization or infection. The vaccines contain an immunogenic amount of a neisserial protein.Type: GrantFiled: September 19, 2003Date of Patent: August 28, 2007Assignee: University of Iowa Research FoundationInventors: Michael A. Apicella, Jennifer L. Edwards
-
Patent number: 7250172Abstract: The present invention is directed to novel polypeptides, polynucleotides and vaccines for use against Neisseria gonorrhoeae colonization or infection. The vaccines contain an immunogenic amount of a neisserial protein.Type: GrantFiled: January 31, 2002Date of Patent: July 31, 2007Assignee: University of Iowa Research FoundationInventors: Michael A. Apicella, Jennifer L. Edwards, Bradford W. Gibson, Karoline Scheffler
-
Patent number: 7235242Abstract: The present invention is concerned with a fragment of IgA1-protease having 40 to 200 amino acid residues and comprising at least 40 amino acids of an amino acid sequence as shown in SEQ ID NO:1, beginning with the amino acid in any one of positions 1 to 5 and ending with an amino acid in any one of positions 40 to 104 or a homologous sequence, its use as a carrier for a conjugate, particularly in combination with a polysaccharide, and a process for producing the peptide as well as vaccines comprising said peptide.Type: GrantFiled: May 7, 2004Date of Patent: June 26, 2007Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften E.V., Pasteur Mérieux Sérums et Vaccins S.A.Inventors: Mark Achtman, Monique Moreau
-
Patent number: 7189405Abstract: The present invention relates to peptide mimics of a conserved gonococcal epitope of Neisseria gonorrhoeae, which epitope is not found on human blood group antigens. This invention also relates to methods and compositions using such peptide mimics for the prophylaxis of gonorrheal infections.Type: GrantFiled: October 27, 2000Date of Patent: March 13, 2007Inventors: Peter A. Rice, Jutamas Ngampasutadol, Sunita Gulati
-
Patent number: 7112332Abstract: An immunogenic complex, essentially consisting of neisserial outer membrane protein proteosomes hydrophobically complexed to native purified bacterial lipopolysaccaride and formulated in accordance with the current invention for mucosal delivery such as via the oral or intranasal route is used as a vaccine. Specifically, a vaccine using shigella lipopolysaccharides complexed to proteosomes for such mucosal administration induces IgG and IgA antibodies in sera and in respiratory and intestinal fluids. Furthermore, such antibodies are associated with protection against shigella infection and these vaccines are herein demonstrated to protect against mucosal infection with shigella.Type: GrantFiled: October 8, 1992Date of Patent: September 26, 2006Assignee: The United States of America as represented by the Secretary of the ArmyInventor: George H. Lowell
-
Patent number: 7081244Abstract: Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensal Neisseria or an extract of a commensal Neisseria. Further methods and compositions comprise conimensal Neisseria which express genes from virulent strains of Neisseria and/or heterologous gene products from non-Neisserial sources. Such compositions are used in vaccine preparations for the treatment of microbial infection.Type: GrantFiled: July 1, 2002Date of Patent: July 25, 2006Assignees: Health Protection Agency, Imperial College Innovations, Ltd.Inventors: Andrew Robinson, Andrew Richard Gorringe, Michael John Hudson, Philippa Bracegirdle, John Simon Kroll, Paul Richard Langford, Steven Anthony Rochford Webb, Keith Cartwright, Cliona Anne O'Dwyer
-
Patent number: 7070781Abstract: A non-toxic mucosal adjuvant is provided which may be admixed with further antigens to provide a vaccine administrable to mucosal surfaces in organisms including man. Preferably, the non-toxic mucosal adjuvant is a detoxified mutant of a bacterial ADP-ribosylating toxin, optionally comprising one or more amino acid additions, deletions or substitutions.Type: GrantFiled: January 24, 2003Date of Patent: July 4, 2006Assignee: Chiron SRLInventor: Rino Rappuoli
-
Patent number: 7029678Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent induces of a range of immune responses.Type: GrantFiled: September 3, 2003Date of Patent: April 18, 2006Assignee: SmithKline Beecham Biologicals (S.A.)Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
-
Patent number: 7018637Abstract: Multivalent immunogenic molecules comprise a carrier molecule containing at least one functional T-cell epitope and multiple different carbohydrate fragments each linker to the carrier molecule and each containing at least one functional B-cell epitope. The carrier molecule inputs enhanced immunogenicity to the multiple carbohydrate fragments. The carbohydrate fragments may be capsular oligosaccharide fragments from Streptococcus pneumoniae, which may be serotypes 1, 4, 5, 6B, 9V, 14, 18C, 19F or 23F, or Neisseria meningitidis, which may be serotype A, B, C, W-135 or Y. Such oligosaccharide fragments may be sized from 2 to 5 kDa. Alternatively, the carbohydrate fragments may be fragments of carbohydrate-based tumor antigens, such as Globo H, LeY or STn. The multivalent molecules may be produced by random conjugation or site-directed conjugation of the carbohydrate fragments to the carrier molecule.Type: GrantFiled: February 23, 1998Date of Patent: March 28, 2006Assignee: Aventis Pasteur, IncInventors: Pele Chong, Alf Lindberg, Michel Klein
-
Patent number: 6994860Abstract: The invention provides Neisseria meningitidis BASB030 polypeptides and polynucleotides encoding BASB030 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are antibodies, diagnostic, prophylactic and therapeutic uses thereof.Type: GrantFiled: May 26, 1999Date of Patent: February 7, 2006Assignee: Smithkline Beecham Biologicals S.A.Inventors: Jean-Louis Ruelle, Johannes Petrus Maria Tommassen
-
Patent number: 6936261Abstract: The present invention generally provides methods and vaccines for the prevention of diseases caused by Neisseria meningitidis bacteria, particularly serogroup B strains.Type: GrantFiled: July 27, 2001Date of Patent: August 30, 2005Assignee: Children's Hospital & Research Center at OaklandInventors: Dan Granoff, Gregory R. Moe
-
Patent number: 6913753Abstract: The invention features incapacitated whole cell bacterial immunogenic compositions produced by infecting a bacterium with Lys minus bacteriophage, which are deficient in the lysin protein. Lys minus bacteriophage retain activity in infection of its appropriate bacterial host, destruction of the bacterial genome, and replication, which are sufficient to inhibit bacterial growth and replication. The resulting, Lys minus-infected bacterium is provided in a state of bacteriostasis, and is not capable of replicating further (e.g., is “incapacitated”). The incapacitated bacterium can then be used as to elicit an immune response for prophylactic and/or therapeutic purposes. The invention thus also features incapacitated bacteria formulated appropriately for use in immunogenic compositions for eliciting an immune response, e.g., for production of antibodies in a non-human host or in a whole cell bacterial vaccine.Type: GrantFiled: September 27, 2002Date of Patent: July 5, 2005Assignee: Gangagen, Inc.Inventors: Janakiraman Ramachandran, Sriram Padmanabhan, Bharathi Sriram
-
Patent number: 6887482Abstract: An isolated, antigenic polypeptide comprises a segment having at least fifty amino acid residues. The amino acid sequence of the segment is present in N. meningitidis, and is different from, but substantially homologous with, the amino acid sequence of a segment of a member of the hemolysin family of toxins.Type: GrantFiled: July 10, 2002Date of Patent: May 3, 2005Assignee: The University of North Carolina at Chapel HillInventors: P. Frederick Sparling, Stuart Thompson
-
Patent number: 6835384Abstract: The invention concerns nucleic acids coding for polypeptides specific of the Neisseria genus pathogenic strains, the corresponding polypeptides, and their diagnostic and therapeutic applications.Type: GrantFiled: August 16, 2001Date of Patent: December 28, 2004Assignees: Aventis Pasteur, Institut National de la Sante et de la Recherche Medicale (INSERM)Inventors: Luc Aujame, Annabelle Bouchardon, Geneviève Renauld-Mongenie, Bachra Rokbi, Xavier Nassif, Colin Tinsley, Agnès Perrin
-
Patent number: 6821521Abstract: A composition comprising Transferrin binding proteins A and B is described (TbpA and TbpB). The composition is suitable for use in vaccines and for treatment of Gram negative bacterial infection, particularly meningococcal infection, demonstrating a broad spectrum of protection to a number of different bacterial pathogens. Also described are compositions comprising Tbps and other components, such as neisserial outer membrane vesicles and Cu,Zn-Superoxide dismutase. Methods for preparation of these compositions and their uses in vaccination against disease are further provided.Type: GrantFiled: August 29, 2001Date of Patent: November 23, 2004Assignee: Health Protection AgencyInventors: Andrew Robinson, Andrew Richard Gorringe, Michael John Hudson, Karen Margaret Reddin
-
Patent number: 6803042Abstract: An immunogenic complex, essentially consisting of neisserial outer membrane protein proteosomes hydrophobically complexed to native purified bacterial lipopolysaccharide and formulated in accordance with the current invention for mucosal delivery such as via the oral or intranasal route is used as a vaccine. Specifically, a vaccine using shigella lipopolysaccharides complexed to proteosomes for such mucosal administration induces IgG and IgA antibodies in sera and in respiratory and intestinal fluids. Furthermore, such antibodies are associated with protection against shigella infection and these vaccines are herein demonstrated to protect against mucosal infection with shigella.Type: GrantFiled: September 28, 1999Date of Patent: October 12, 2004Assignee: U.S. Army Medical Research Materiel CommandInventor: George H. Lowell
-
Patent number: 6797274Abstract: The invention provides BASB047, BASB054, BASB068 and BASB069 polypeptides, and polynucleotides encoding BASBO47, BASB054, BASB068 and BASB069 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: December 31, 2001Date of Patent: September 28, 2004Assignee: GlaxoSmithKline Biologicals S.A.Inventor: Jean-Louis Ruelle
-
Patent number: 6797273Abstract: The invention provides BASB053 polypeptides and polynucleotides encoding BASB053 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: January 17, 2002Date of Patent: September 28, 2004Assignee: GlaxoSmithKline Biologicals S.A.Inventor: Jean-Louis Ruelle
-
Patent number: 6770284Abstract: The invention provides BASB040 polypeptides and polynticleotides from Neisseria meningitidis encoding BASB040 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: September 21, 2001Date of Patent: August 3, 2004Assignee: GlaxoSmithKline Biological S.A.Inventor: Jean-Louis Ruelle
-
Patent number: 6756493Abstract: The invention discloses the Neisseria spp. NGSP polypeptide, polypeptides derived therefrom (NGSP-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the NGSP polypeptide and/or NGSP-derived polypeptides. Also disclosed are prophylactic or therapeutic compositions, including antigenic, preferably immunogenic compositions, e.g., vaccines, comprising NGSP polypeptide and/or a NGSP-derived polypeptide or antibodies thereto. The invention additionally discloses methods of inducing an immune response to Neisseria and Neisseria NGSP polypeptide and an NGSP-derived polypeptide in animals.Type: GrantFiled: August 31, 1999Date of Patent: June 29, 2004Assignee: Antex Biologics, Inc.Inventors: W. James Jackson, Andrea M. Harris
-
Patent number: 6743607Abstract: Compositions and methods for making complex carbohydrates in a bacterial production cell are disclosed. The complex carbohydrates that can be made include oligosaccharides and polysaccharides of bacterial or mammalian origin.Type: GrantFiled: November 16, 2001Date of Patent: June 1, 2004Assignees: The Regents of the University of California, The University of Iowa Research FoundationInventors: Michael A. Apicella, Bradford W. Gibson, Nancy J. Phillips
-
Patent number: 6743900Abstract: Improved forms of vaccines which comprise proteosomes and protein antigens are described. Vaccines which contain influenza HA as the antigen are used for illustration as to demonstrate efficacy. Improvements in the preparation of the vaccines themselves and the proteosome component are also included.Type: GrantFiled: February 15, 2001Date of Patent: June 1, 2004Assignee: ID Biomedical Corporation of QuebecInventors: David S. Burt, David Hugh Jones, George H. Lowell, Gregory Lee White, Kirkor Torossian, Louis F. Fries, III, Martin Plante
-
Publication number: 20040101537Abstract: A combination of CpG oligonucleotides and polymer microparticles is an extremely effective adjuvant for Neisserial antigens. The invention therefore provides a composition comprising: (a) a Neisserial antigen; (b) a CpG oligonucleotide; and (c) a biodegradable polymer microparticle.Type: ApplicationFiled: October 3, 2002Publication date: May 27, 2004Inventors: Derek O'Hagan, Nicholas Valiante
-
Patent number: 6709660Abstract: The invention provides proteins from Neisseria meningitidis (strains A & B), including amino acid sequences, the corresponding nucleotide sequences, expression data, and serological data. The proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics.Type: GrantFiled: April 30, 1999Date of Patent: March 23, 2004Assignee: Chrion S.r.l.Inventors: Vincenzo Scarlato, Vega Masignani, Rino Rappuoli, Mariagrazia Pizza, Guido Grandi
-
Patent number: 6706270Abstract: The invention provides BASB041, 43, 44 and 48 polypeptides and polynucleotides encoding BASB041, 43, 44 and 48 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: September 6, 2001Date of Patent: March 16, 2004Assignee: SmithKline Beecham Biologicals s.a.Inventors: Jean-Louis Ruelle, Vincent Georges Christian Louis Verlant
-
Patent number: 6664094Abstract: This invention relates to mutants of Neisseria useful for vaccine preparation. Specifically this invention relates to mutants of Neisseria containing mutations in a major outer membrane protein gene such that no immunologically functional polypeptides encoded by said gene are produced. More specifically, the invention relates to a mutant strain of Neisseria gonorrhoeae having a mutation of the PIII gene and to vaccines derived therefrom.Type: GrantFiled: September 21, 1994Date of Patent: December 16, 2003Assignee: The Rockefeller UniversityInventors: Emil Claus Gotschlich, Lee Mark Wetzler, Milan Scott Blake, John Michael Koomey
-
Patent number: 6656472Abstract: Multivalent immunogenic molecules comprise a carrier molecule containing at least one functional T-cell epitope and multiple different carbonhydrate fragments each linked to the carrier molecule and each containing at least one functional B-cell epitope. The carrier molecule inparts enhanced immunogenicity to the multiple carbohydrate fragments. The carbohydrate fragments may be capsular oligosaccharide fragments from Streptococcus pneumoniae which may be serotypes (1, 4, 5, 6B, 9V, 14, 18C, 19F or 23F), or Neisseria meningitidis, which may be serotype (A, B, C) W-135 or Y. Such oligosaccharide fragments may be sized from about 2 to about 5 kDa. Alternatively, the carbohydrate fragments may be fragments of carbohydrate-based tumor antigens, such as Globo H, LeY or STn. The multivalent molecules may be produced by random conjugation or site-directed conjugation of the carbohydrate fragments to the carrier molecule.Type: GrantFiled: December 22, 2000Date of Patent: December 2, 2003Assignee: Aventis Pasteur LimitedInventors: Pele Chong, Alf Lindberg, Michel H. Klein
-
Patent number: 6627204Abstract: The invention provides BASB033 polypeptides and polynucleotides encoding BASB033 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: July 18, 2001Date of Patent: September 30, 2003Assignee: SmithKline Beecham Biologicals s.a.Inventor: Jean-Louis Ruelle
-
Patent number: 6623739Abstract: The present invention provides vaccine compositions comprising an oil-in-water emulsion optionally with 3 De-O-acylated monophosphoryl lipid A and QS21. The vaccine compositions are potent inducers of a range of immune responses.Type: GrantFiled: February 24, 2000Date of Patent: September 23, 2003Assignee: SmithKline Beecham Biologicals s.a.Inventors: Patricia Marie Momin, Nathalie Marie-Josephe Garcon
-
Patent number: 6613336Abstract: Disclosed is an H. influenzae type b polysaccharide-meningococcal outer membrane protein conjugate, pharmaceutical compositions thereof, and the use thereof to induce an immune response to H. influenzae in an animal.Type: GrantFiled: May 10, 2002Date of Patent: September 2, 2003Assignee: Baxter International Inc.Inventors: Milan S. Blake, Francis Michon, Peter C. Fusco, Iver Heron
-
Publication number: 20030161834Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.Type: ApplicationFiled: March 3, 2003Publication date: August 28, 2003Applicant: SmithKline Beecham Biologicals s.a.Inventors: Martin Friede, Nathalie Garcon, Catherine Marie Ghislaine Gerard, Philippe Hermand
-
Patent number: 6558677Abstract: A mucosal vaccine for Neisseria based on native outer membrane vesicles (NOMV) prepared from genetically engineered vaccine strain and unexposed to detergents is described. Methods for extending this vaccine approach to other Gram negative bacteria are also decribed.Type: GrantFiled: November 15, 1996Date of Patent: May 6, 2003Inventors: Wendell D. Zollinger, David R. Shoemaker, Agnes G. Saunders, Brenda L. Brandt
-
Patent number: 6548287Abstract: The present invention provides gram-negative bacterial strains that produce substantially pure non-pyrogenic lipopolysaccharide or lipid A. The present invention also relates to a use of said strains for the preparation of non-pyrogenic DNA and use of the same for introducing endogenous or foreign genes into animal cells or animal tissue. Further, the present invention relates to a use of said strains for the preparation of non-pyrogenic recombinant mammalian, protozoan and viral proteins. Furthermore, the present invention relates to a use of said strains for the preparation of non-pyrogenic bacterial vaccines and vaccine vectors. Yet a further use of the present invention relates to a use of said strains for the preparation of non-pyrogenic bacterial proteins and polysaccharides antigens for use as vaccines.Type: GrantFiled: June 24, 1999Date of Patent: April 15, 2003Assignee: University of Maryland, BaltimoreInventors: Robert J. Powell, David M. Hone
-
Patent number: 6544518Abstract: The present invention relates to adjuvant compositions which are suitable to be used in vaccines. In particular, the adjuvant compositions of the present invention comprises a saponin and an immunostimulatory oligonucleotide, optionally with a carrier. Also provided by the present invention are vaccines comprising the adjuvants of the present invention and an antigen. Further provided are methods of manufacture of the adjuvants and vaccines of the present invention and their use as medicaments. Methods of treating an individual susceptible to or suffering from a disease by the administration of the vaccines of the present invention are also provided.Type: GrantFiled: October 18, 2000Date of Patent: April 8, 2003Assignee: SmithKline Beecham Biologicals s.a.Inventors: Martin Friede, Nathalie Garcon, Catherine Marie Ghislaine Gerard, Philippe Hermand
-
Publication number: 20030059444Abstract: A mucosal vaccine for Neisseria based on native outer membrane vesicles (NOMV) prepared from genetically engineered vaccine strain and unexposed to detergents is described. Methods for extending this vaccine approach to other Gram negative bacteria are also decribed.Type: ApplicationFiled: November 15, 1996Publication date: March 27, 2003Inventors: WENDELL D. ZOLLINGER, DAVID R. SHOEMAKER, AGNES G. SAUNDERS, BRENDA L. BRANDT
-
Publication number: 20030026809Abstract: Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensal Neisseria or an extract of a commensal Neisseria. Further methods and compositions comprise commensal Neisseria which express genes from virulent strains of Neisseria and/or heterologous gene products from non-neisserial sources. Such compositions are used in vaccine preparations for the treatment of microbial infection.Type: ApplicationFiled: August 31, 2001Publication date: February 6, 2003Inventors: Andrew Robinson, Andrew Richard Gorringe, Michael John Hudson, Philippa Bracegirdle, John Simon Kroll, Paul Richard Langford, Steven Anthony Rochford Webb, Keith Cartwright, Cliona Anne O'Dwyer, Karen Margaret Reddin
-
Publication number: 20030021812Abstract: Methods and compositions for the treatment of microbial infection, and in particular meningococcal disease, comprise a commensal Neisseria or an extract of a commensal Neisseria. Further methods and compositions comprise commensal Neisseria which express genes from virulent strains of Neisseria and/or heterologous gene products from non-Neisserial sources. Such compositions are used in vaccine preparations for the treatment of microbial infection.Type: ApplicationFiled: July 1, 2002Publication date: January 30, 2003Applicant: Microbiological Research AuthorityInventors: Andrew Robinson, Andrew Richard Gorringe, Michael John Hudson, Philippa Bracegirdle, John Simon Kroll, Paul Richard Langford, Steven Anthony Rochford Webb, Keith Cartwright, Cliona Anne O'Dwyer
-
Patent number: 6476201Abstract: A continuous method for preparing proteosome-amphiphilic determinant vaccines for parenteral or mucosal administration using diafiltration or ultrafiltration technology. The amphiphilic determinants include lipopolysaccharides from gram negative bacteria, e.g. S. flexneri, P. shigelloides and S. sonnei. Proteosomes are obtained from group B type 2b meningococci. The active proteosome-amphiphilic determinant complexes (non-covalent complexes) of the vaccine are formed using diafiltration or ultrafiltration to remove the detergent under non-static conditions. The use of diafiltration or ultrafiltration decreases processing time and the opportunity for contamination and further permits the use of ambient temperature and efficient scale-up. In addition, the process permits the reliable and continuous monitoring of the dializate which enhances the efficiency of the entire process.Type: GrantFiled: July 27, 1998Date of Patent: November 5, 2002Assignees: ID Biomedical Corporation of Quebec, The United States of America as represented by the Secretary of the ArmyInventors: George H. Lowell, Wendell D. Zollinger, James F. Wood
-
Publication number: 20020136741Abstract: Described herein is a method for removing toxic lipooligosaccharide (LOS) from outer membranes of Gram-negative cocci, such as Neisseria meningitidis.LOS-depleted outer membranes and LOS-depleted soluble outer membrane proteins can be prepared, which are able to elicit bactericidal antibodies against homologous strains of bacteria. Vaccines and other uses of the preparations are further described.Type: ApplicationFiled: March 5, 2002Publication date: September 26, 2002Applicant: American Cyanamid CompanyInventor: Gary W. Zlotnick